Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer: A UK Perspective Considering Duration of Benefit, Long-Term Toxicity and Pattern of Recurrence

Author： Hall Peter S.   Hulme Claire   McCabe Christopher   Oluboyede Yemi   Round Jeff   Cameron David A.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.29, Iss.5, 2011-05, pp. : 415-432

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer

By Norum Jan  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 12, 2006-08 ,pp. : 1617-1625

Informa Healthcare

Access to resources Recommend Favorite

Trastuzumab cost effectiveness in the UK updated

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 629, 2011-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer: A Lifetime Model

By Millar J. Alasdair   Millward Michael J.  

PharmacoEconomics, Vol. 25, Iss. 5, 2007-01 ,pp. : 429-442

Adis International

Access to resources Recommend Favorite

An introduction to cost-effectiveness and cost–benefit analysis of pharmacogenomics

By Phillips Kathryn A   Veenstra David   Bebber Stephanie Van   Sakowski Julie  

Pharmacogenomics, Vol. 4, Iss. 3, 2003-05 ,pp. : 231-239

Future Medicine

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective: Doxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide

By Liubao Peng  

PharmacoEconomics, Vol. 27, Iss. 10, 2009-10 ,pp. : 873-886

Adis International

Access to resources Recommend Favorite